Get the Stockscreener App
15.22
4.93%
-0.79
Prothena Corporation Plc stock is traded at $15.22, with a volume of 1.52M.
It is down -4.93% in the last 24 hours and up +5.69% over the past month.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
See More
Previous Close:
$16.01
Open:
$15.89
24h Volume:
1.52M
Relative Volume:
2.52
Market Cap:
$818.97M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-10.72
EPS:
-1.42
Net Cash Flow:
$-100.85M
1W Performance:
+19.00%
1M Performance:
+5.69%
6M Performance:
-22.58%
1Y Performance:
-58.78%
1-Day Range:
$15.10
$16.42
1-Week Range:
$11.70
$17.66
52-Week Range:
$11.70
$41.55
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
15.22 | 818.97M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
HC Wainwright Reiterates "Buy" Rating for Prothena (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Now Covered by Chardan Capital - MarketBeat
Demystifying Prothena Corp: Insights From 6 Analyst Reviews - Benzinga
Even after rising 16% this past week, Prothena (NASDAQ:PRTA) shareholders are still down 67% over the past three years - Simply Wall St
Prothena Corp (NASDAQ:PRTA) Stock Quotes, Forecast and News Summary - Benzinga
Prothena Shares Surge 43% Despite Setback in Parkinson's Drug Trial, Investors Eye Future Potential - mediahousepress
Prothena stock soars despite study miss By Investing.com - Investing.com Canada
Prothena stock soars despite study miss - Investing.com
Bank of America Lowers Prothena (NASDAQ:PRTA) Price Target to $22.00 - MarketBeat
Why Is Prothena Corp Stock Soaring Today?Roche Holding (OTC:RHHBY) - Benzinga
Prothena shares price target cut after Parkinson's study miss By Investing.com - Investing.com UK
Prothena stock gains despite Parkinson’s setback (RHHBY:OTCQX) - Seeking Alpha
Prothena (NASDAQ:PRTA) Hits New 52-Week LowHere's Why - MarketBeat
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease - Business Wire
Prothena (NASDAQ:PRTA) Stock Price Down 3.6%Time to Sell? - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Up 7.8%What's Next? - MarketBeat
Where are the Opportunities in (PRTA) - Stock Traders Daily
Prothena's SWOT analysis: biotech stock's high-risk, high-reward pipeline - Investing.com
Oppenheimer bullish on Prothena stock, sees $1B opportunity for birtamimab in rare disease - Investing.com UK
Janus Henderson Group PLC Sells 1,008,511 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Reaches New 1-Year LowWhat's Next? - MarketBeat
Charles Schwab Investment Management Inc. Decreases Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? - Yahoo Finance
Wellington Management Group LLP Has $69.91 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
FY2024 EPS Estimates for Prothena Increased by Analyst - MarketBeat
Systematic Financial Management LP Sells 185,638 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
FY2024 EPS Estimates for Prothena Raised by Zacks Research - Defense World
Prothena's SWOT analysis: high-risk pipeline stock faces crucial readouts - Investing.com India
Prothena's SWOT analysis: high-risk pipeline stock faces crucial readouts By Investing.com - Investing.com South Africa
Learn to Evaluate (PRTA) using the Charts - Stock Traders Daily
Prothena (NASDAQ:PRTA) Rating Lowered to “Sell” at StockNews.com - Defense World
Prothena FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Prothena FY2024 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
FY2024 EPS Estimates for Prothena Reduced by HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Hits New 12-Month LowHere's What Happened - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average PT from Brokerages - Defense World
FY2028 EPS Estimates for Prothena Increased by HC Wainwright - MarketBeat
Prothena's SWOT analysis: stock poised for potential breakthroughs amid risks - Investing.com India
Expert Ratings For Prothena Corp - Benzinga
Prothena's (PRTA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus - Yahoo Finance
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena: Q3 Earnings Snapshot - Marketscreener.com
Prothena Corp PLC Reports Q3 2024 EPS Loss of $1.10, Beats Estimate; Revenue Misses at $1.0 Million - GuruFocus.com
Prothena Reports $59M Q3 Loss, Pipeline Updates Signal Key Trial Results in 2024-25 | PRTA Stock News - StockTitan
Prothena Corporation plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average Target Price from Brokerages - MarketBeat
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corporation Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Walker Karin L | Chief Accounting Officer |
Jan 24 '24 |
Sale |
34.00 |
5,000 |
170,000 |
0 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):